CIK 0001802768 · Large accelerated filer
Royalty Pharma plc
Sign in to watch- Ticker
- RPRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- (212) 883-0200
- Business address
- 110 EAST 59TH STREET, NEW YORK, NY, 10022
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,324,753
- in 4 filings, $12.3M under 10b5-1 plans
Net −$12,324,753. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −1,292 | $46.67 | $60K | 46,344 |
| 2026-03-02 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −583 | $47.01 | $27K | 45,761 |
| 2026-02-23 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −32,916 | $45.32 | $1.5M | 131,664 |
| 2026-02-23 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −1,875 | $45.32 | $85K | 47,636 |
| 2026-02-11 | Urist Marshall EVP, Research & Investments | Grant or award | +19,970 | 27,368 | ||
| 2026-02-11 | Coyne Terrance P. EVP & CFO | Grant or award | +26,626 | 49,511 | ||
| 2026-02-11 | Hite Christopher EVP & Vice Chairman | Grant or award | +26,626 | 685,136 | ||
| 2026-02-11 | Legorreta Pablo G. CEO, Chairman of the Board | Grant or award | +157,828 | 1,098,783 | ||
| 2026-02-04 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −19,076 | $43.29 | $826K | 164,580 |
| 2026-02-04 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −1,087 | $43.29 | $47K | 22,885 |
| 2026-02-03 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −108,759 | $42.84 | $4.7M | 183,656 |
| 2026-02-03 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −6,195 | $42.84 | $265K | 23,972 |
| 2026-02-02 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −102,581 | $42.08 | $4.3M | 292,415 |
| 2026-02-02 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −5,843 | $42.08 | $246K | 30,167 |
| 2026-01-30 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 | −20,000 | $41.09 | $822K | 0 |
| 2026-01-23 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 | −20,000 | $40.26 | $805K | 20,000 |
| 2026-01-20 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −65,832 | $39.35 | $2.6M | 394,996 |
| 2026-01-20 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −3,750 | $39.35 | $148K | 36,010 |
| 2026-01-16 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 | −20,000 | $39.52 | $790K | 40,000 |
| 2026-01-09 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 | −20,000 | $40.78 | $816K | 60,000 |
Page 4 of 8 · 159 trades